A clinical study comparing pharmacokinetics, safety, and tolerability of FYB202 with reference drug Stelara
Phase of Trial: Phase I
Latest Information Update: 28 Oct 2019
Price : $35 *
At a glance
- Drugs Ustekinumab (Primary)
- Indications Immunological disorders
- Focus Adverse reactions
- Sponsors Bioeq
- 28 Oct 2019 According to a Formycon media release, dosing of study subjects in this trial started last week. Bioeq GmbH is the sponsor of the clinical trial and is also responsible for the study design and clinical operation.
- 28 Oct 2019 Status changed from planning to recruiting, as reported in a Formycon media release.
- 06 Dec 2018 New trial record